65,437 trials
Radiodermatitis · Quality of Life
Primary: Proportion of Patients Without Grade G2 Skin Toxicity Radiodermatitis at Week 5 — 10; 5; 13; 11 participants
Traumatic Brain Injury (TBI) · Hazardous and Harmful Alcohol Use
Primary: Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB) — 26.2; 26.5 change in percent heavy drinking days/wk
Tattoos
Primary: Tattoo Clearance Using Photographic Evaluation — 15; 6; 2 Tattoos
Heart Rate Variability
Primary: Heart Rate Variability (HRV) — 1439; 2191 ms2
Carcinoma, Non-Small-Cell Lung
Primary: Overall Response Rate — 42.5; 15.8 percentage of responders
Smoking
Primary: Self- Control as Measured by the Change in the Length of Time Participants Can Hold a Hand-grip at Baseline and Follow-up (One Week After Baseline) — -9.36; 2.76; -4.32…
Type 2 Diabetes
Primary: Change in Late Outgrowth Endothelial Progenitor Colonies — 0.3; 0.2; 3.1; 0.1 LOEPC colonies — p=<0.05
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Post Surgical Incisions From Abdominoplasty Procedures
Primary: Scar Evaluation at End of Treatment Period Comparing Treated to Standard of Care (Control) — 18.64; 50.52 score on a scale
Medication Adherence
Primary: Medication Adherence — 85.36; 86.79; 81.93; 86.09 Percentage
Amputation · Artificial Limb
Primary: Ratio Between Sound and Prosthetic Side Step Lengths — 0.88; 0.87; 1.02; 0.91 Sound step length / Pros. step length
Pharmacokinetics
Primary: Plasma Nicotine Concentration-time Profile — 0.563; 0.563; 0.928; 1.02 ng/ml
Lung; Node
Primary: Number of Participants With Device or Procedure Related Adverse Events — 2 Participants
Stroke, Acute
Primary: Number of Subjects With mRS Score of 0 to 2 — 329; 337 Participants — p=0.335
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants